Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW FRANCIS TRAINER

Allopathic & Osteopathic Physicians Urology

NPI
1477556561
CMS profile
293867
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,022.96

90 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,923.06 88
Gift $99.90 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW FRANCIS TRAINER

NPI 1477556561 · CMS profile ID 293867

Allopathic & Osteopathic Physicians / Urology

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1477556561?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW FRANCIS TRAINER, NPI 1477556561, CMS profile ID 293867. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477556561?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANDREW FRANCIS TRAINER, NPI 1477556561, CMS profile ID 293867. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477556561?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANDREW FRANCIS TRAINER, NPI 1477556561, CMS profile ID 293867, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1477556561?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

90 matching records · $2,022.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 90 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–90 of 90.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $11.6006/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131266309 CMS
Janssen Biotech, Inc. $14.7905/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078340068 CMS
Verity Pharmaceuticals Inc. $17.4005/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080598503 CMS
UROGEN PHARMA, INC. $13.9705/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137918487 CMS
Tolmar, Inc. $22.3205/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138713050 CMS
Sumitomo Pharma America, Inc. $0.5805/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929038 CMS
Sumitomo Pharma America, Inc. $17.7505/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929040 CMS
PFIZER INC. $8.4905/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131266305 CMS
Novartis Pharmaceuticals Corporation $16.2804/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087427860 CMS
Novo Nordisk Inc $19.3904/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097326983 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.5304/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086189964 CMS
Merck Sharp & Dohme LLC $14.7604/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141627651 CMS
Astellas Pharma US Inc $17.7904/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139305128 CMS
Sumitomo Pharma America, Inc. $54.0204/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929036 CMS
Sumitomo Pharma America, Inc. $15.0504/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929034 CMS
PFIZER INC. $9.2104/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131266301 CMS
Verity Pharmaceuticals Inc. $18.4304/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080598515 CMS
COLOPLAST CORP $16.8403/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117441940 CMS
COLOPLAST CORP $18.0603/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117441956 CMS
Sumitomo Pharma America, Inc. $0.8203/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929030 CMS
Sumitomo Pharma America, Inc. $17.0703/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929032 CMS
PFIZER INC. $7.8203/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131266297 CMS
Sumitomo Pharma America, Inc. $11.0903/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929026 CMS
Sumitomo Pharma America, Inc. $17.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929028 CMS
Sumitomo Pharma America, Inc. $13.6203/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929024 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.7002/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086207435 CMS
Janssen Biotech, Inc. $13.2402/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078341689 CMS
PROCEPT BioRobotics Corporation $119.7002/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144029004 CMS
Laborie Medical Technologies Corp. $92.0802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154325437 CMS
PFIZER INC. $9.6602/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131267021 CMS
Janssen Biotech, Inc. $18.5602/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078339738 CMS
Verity Pharmaceuticals Inc. $13.5102/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080598507 CMS
Astellas Pharma US Inc $17.1002/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139290894 CMS
Sumitomo Pharma America, Inc. $15.0502/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929022 CMS
Tolmar, Inc. $18.3401/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138709862 CMS
Novartis Pharmaceuticals Corporation $25.1101/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087427858 CMS
Merck Sharp & Dohme LLC $16.8601/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141627647 CMS
Sumitomo Pharma America, Inc. $19.2501/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929018 CMS
Sumitomo Pharma America, Inc. $0.5801/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148929020 CMS
PFIZER INC. $8.5601/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131266293 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,634.67 77
PY2020 $934.60 43
PY2021 $1,290.78 78
PY2022 $1,328.85 82
PY2023 $2,957.89 115
PY2024 $2,022.96 90
PY2025 $1,750.77 79

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $108,499.96 19
PY2024 Principal investigator $107,867.76 26
PY2023 Principal investigator $63,322.05 20
PY2022 Principal investigator $47,730.53 17
PY2021 Principal investigator $39,093.37 28
PY2020 Principal investigator $168,854.02 57
PY2019 Principal investigator $304,474.48 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ferring Pharmaceuticals AS $9,791.25 12/24/2025 Non-covered Recipient Entity
ADULT AND PEDIATRIC UROLOGY PC
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1242061389
Principal investigator 1 Ferring Pharmaceuticals AS $6,528.04 12/24/2025 Non-covered Recipient Entity
ADULT AND PEDIATRIC UROLOGY PC
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1242061393
Principal investigator 1 PFIZER INC. $15,800.00 10/30/2025 Non-covered Recipient Entity
The Urology Center PC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228741501
Principal investigator 1 PFIZER INC. $3,000.00 10/30/2025 Non-covered Recipient Entity
Adult Pediatric Urology PC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228756859
Principal investigator 1 Ferring Pharmaceuticals AS $500.00 10/23/2025 Non-covered Recipient Entity
ADULT AND PEDIATRIC UROLOGY PC
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1242061237
Principal investigator 1 Ferring Pharmaceuticals AS $19,280.00 09/25/2025 Non-covered Recipient Entity
THE UROLOGY CENTER PC
A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects With Low-grade Upper Tract Urothelial Carcinoma (LG-UTUC) No dispute reported 06/30/2026 1242061068
Principal investigator 1 Ferring Pharmaceuticals AS $10,318.05 09/11/2025 Non-covered Recipient Entity
ADULT AND PEDIATRIC UROLOGY PC
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1242060999
Principal investigator 1 Ferring Pharmaceuticals AS $2,673.68 09/04/2025 Non-covered Recipient Entity
ADULT AND PEDIATRIC UROLOGY PC
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1242060941
Principal investigator 1 PFIZER INC. $800.00 08/09/2025 Non-covered Recipient Entity
Adult Pediatric Urology PC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228767881
Principal investigator 1 Ferring Pharmaceuticals AS $2,500.00 07/25/2025 Non-covered Recipient Entity
ADULT AND PEDIATRIC UROLOGY PC
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1242060812
Principal investigator 1 Ferring Pharmaceuticals AS $1,449.00 07/18/2025 Non-covered Recipient Entity
ADULT AND PEDIATRIC UROLOGY PC
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1242060743
Principal investigator 1 Dendreon Pharmaceuticals LLC $650.00 06/23/2025 Non-covered Recipient Entity
UROLOGY OF VIRGINIA PLLC
ProvONE No dispute reported 06/30/2026 1247892220
Principal investigator 1 Dendreon Pharmaceuticals LLC $20,090.61 06/06/2025 Non-covered Recipient Entity
UROLOGY OF VIRGINIA PLLC
ProvONE No dispute reported 06/30/2026 1247892205
Principal investigator 1 Novartis Pharmaceuticals Corporation $705.68 05/27/2025 Non-covered Recipient Entity
UROHEALTH PARTNERS
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190308034
Principal investigator 1 Sumitomo Pharma America, Inc. $3,500.00 04/09/2025 Non-covered Recipient Entity
ADULT & PEDIATRIC UROLOGY PC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176632893
Principal investigator 1 PFIZER INC. $4,512.13 02/01/2025 Non-covered Recipient Entity
ADULT PEDIATRIC UROLOGY PC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228771298
Principal investigator 1 PFIZER INC. $358.50 02/01/2025 Non-covered Recipient Entity
ADULT PEDIATRIC UROLOGY PC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228773868
Principal investigator 1 PFIZER INC. $5,377.47 02/01/2025 Non-covered Recipient Entity
ADULT PEDIATRIC UROLOGY PC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228774206
Principal investigator 1 Sumitomo Pharma America, Inc. $665.55 01/29/2025 Non-covered Recipient Entity
ADULT & PEDIATRIC UROLOGY PC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176625011